BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt

PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations

(2015) Katsuhiko Nosho et al.   NEOPLASIA

Synthesis and SAR Studies of Dual AKT/NF-κB Inhibitors Against Melanoma

(2013) Elisa Barile et al.   Chemical Biology & Drug Design

Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer

(2013) Shashi Rajput et al.   PLoS One

PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes

(2012) Ipsita Pal et al.   ACTA PHARMACOLOGICA SINICA

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

(2012) Pat Gulhati et al.   CARCINOGENESIS

AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers

(2012) Michael J. Gray et al.   INTERNATIONAL JOURNAL OF CANCER

GRP78 Knockdown Enhances Apoptosis via the Down-Regulation of Oxidative Stress and Akt Pathway after Epirubicin Treatment in Colon Cancer DLD-1 Cells

(2012) Yu-Jia Chang et al.   PLoS One

Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways

(2011) Yongmei Feng et al.   Pigment Cell & Melanoma Research

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity

(2011) R. Dash et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glucose regulated protein 78 (GRP78) is overexpressed in colorectal carcinoma and regulates colorectal carcinoma cell growth and apoptosis

(2010) Xiaoming Xing et al.   ACTA HISTOCHEMICA

ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells

(2010) Siddik Sarkar et al.   CANCER BIOLOGY & THERAPY

Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells

(2010) R Dash et al.   CANCER GENE THERAPY

mda-7/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity

(2010) Rupesh Dash et al.   CYTOKINE & GROWTH FACTOR REVIEWS

ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells

(2010) Siddik Sarkar et al.   JOURNAL OF CELLULAR PHYSIOLOGY

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Induction of Akt Activity by Chemotherapy Confers Acquired Resistance

(2009) Wei-Chien Huang et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma

(2009) Supriya Gaitonde et al.   Pigment Cell & Melanoma Research

Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus

(2008) Rupert Langer et al.   BMC CANCER

Molecular Basis of Nuclear Factor- B Activation by Astrocyte Elevated Gene-1

(2008) D. Sarkar et al.   CANCER RESEARCH

AKT Signaling in Regulating Angiogenesis

(2008) Bing-Hua Jiang et al.   CURRENT CANCER DRUG TARGETS

In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells

(2008) Zhijian Chen et al.   JOURNAL OF NEURO-ONCOLOGY

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

(2008) Johan Bussink et al.   LANCET ONCOLOGY